Increased Positive Predictive Value for a Single-Nucleotide Polymorphism-Based Non-invasive Prenatal Test for the 22q11.2 Deletion
Tóm tắt
Non-invasive prenatal testing (NIPT) has expanded its coverage beyond the common aneuploidies to include subchromosomal abnormalities such as the 22q11.2 deletion through the analysis of cell-free DNA. We previously reported a positive predictive value (PPV) of 18% and false-positive rate (FPR) of 0.38% for a single-nucleotide polymorphism (SNP)-based NIPT for fetal 22q11.2 deletion in a clinical cohort. Herein, we assess the performance of the test following methodology changes that include sequencing high-risk calls at high depth of read (HDOR) and raising the confidence threshold of the algorithm from 0.90 to 0.95. At the original confidence cut-off, a PPV of 42.3% upon reflex-sequencing of high-risk samples at a HDOR was reported. Raising the algorithm’s confidence threshold further increased the PPV to 52.4% and reduced the FPR to 0.07%, with no loss in test sensitivity. The PPV was 100% for high a priori risk cases, and 20% for low a priori risk cases. The improved assay performance documented with the updated methodology supports the efficacy of the SNP-based NIPT in the detection of fetal 22q11.2 deletion.
Tài liệu tham khảo
Grati FR, Molina Gomes D, Ferreira JC, Dupont C, Alesi V, Gouas L, et al. Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies. Prenat Diagn. 2015;35(8):801–9.
McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071. https://doi.org/10.1038/nrdp.2015.71.
Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol. 2013;42(1):15–33.
Wapner RJ, Babiarz JE, Levy B, Stosic M, Zimmermann B, Sigurjonsson S, et al. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol. 2015;212(3):332-e1–9.
Srinivasan A, Bianchi DW, Huang H, Sehnert AJ, Rava RP. Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. Am J Hum Genet. 2013;92(2):167–76.
Zhao C, Tynan J, Ehrich M, Hannum G, McCullough R, Saldivar JS, et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin Chem. 2015;61(4):608–16.
Schmid M, Wang E, Bogard PE, Bevilacqua E, Hacker C, Wang S, et al. Prenatal screening for 22q11.2 deletion using a targeted microarray-based cell-free DNA test. Fetal Diagn Ther. 2017. https://doi.org/10.1159/000484317.
Helgeson J, Wardrop J, Boomer T, Almasri E, Paxton WB, Saldivar JS, et al. Clinical outcome of subchromosomal events detected by whole-genome noninvasive prenatal testing. Prenat Diagn. 2015;35(10):999–1004.
Gross SJ, Stosic M, McDonald-McGinn DM, Bassett AS, Norvez A, Dhamankar R, et al. Clinical experience with single-nucleotide polymorphism-based non-invasive prenatal screening for 22q11.2 deletion syndrome. Ultrasound Obstet Gynecol. 2016;47(2):177–83.
Martin K, Iyengar S, Kalyan A, Lan C, Simon AL, Stosic M, et al. Clinical experience with a single-nucleotide polymorphism-based non-invasive prenatal test for five clinically significant microdeletions. Clin Genet. 2017. https://doi.org/10.1111/cge.13098:1-8.